and the exclusion of other pathologies, such as those associated with Alzheimer's disease (AD) and Lewy body disorders [ 7 ] . Familial cases (oft en with much younger onset than typical sporadic cases) with identical neuopathological features may be a result of FTDP-17 associated with specifi c mutations in the tau gene.
Introduction and history
While historical review suggests earlier reports of the entity now known as corticobasal degeneration (CBD), the disease was fi rst clearly described in a series of three cases in 1968, when it was termed corticodentatonigral degeneration with neuronal achromasia [ 1 ] . Subsequent terminology has included corticonigral degeneration with neuronal achromasia [ 2 ] , corticobasal ganglionic degeneration [ 3 ] , cortical-basal ganglionic degeneration [ 4 ] , and corticobasal degeneration [ 5 ] . While the more precise terminology of corticalbasal ganglionic degeneration (CBGD) may be favored, the most commonly used descriptor today is CBD.
As understanding of this complex disease process has grown over the forty years since the original clinicopathological series, it has become clear that the corticobasal spectrum involves a clinical syndrome and a pathological entity that only sometimes overlap ( Figure 5 .1 ). Because of this, the clinical diagnosis is now labeled the corticobasal syndrome (CBS) while the term CBD is reserved for pathologically confi rmed diagnoses [ 6 ] . As will be discussed further, the pathological entity of CBD is associated with varying clinical presentations that can change even in a single individual over time, while CBS is associated with a variety of fi ndings on pathological examination. It is only in this context that the current understanding of CBD can be discussed. Th e overlap of CBS, CBD, and related disorders is considerable, making accurate clinical diagnosis challenging and emphasizing the need for continued research.
Because CBD is a pathological diagnosis, discussion of this entity must begin with neuropathological fi ndings. CBD is a sporadic neurodegenerative process related to abnormal aggregation of hyperphosphorylated tau. Tau is a microtubule-associated protein the role of which in the neuron is to promote microtubule assembly and stabilization. Other tauopathies include frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear palsy (PSP), and Pick's disease (PiD). In particular, CBD is associated with abnormal insoluble tau isoforms with four conserved repeat sequences (4R tau), discussed further in the following sections.
Th e Offi ce of Rare Diseases published criteria for CBD in 2002 ( Table 5 .1 ). Th e crit eria emphasize the presence of tau-immunoreactive lesions in addition to the presence of ballooned neurons, cortical atrophy, and nigral degeneration [ 7 ] . Diagnosis is based on histopathological fi ndings, although gross fi ndings can provide supportive information. Confi rmation of the diagnosis requires identifi cation of the pathological features of CBD and the exclusion of other pathologies, such as those associated with Alzheimer's disease (AD) and Lewy body disorders [ 7 ] . Familial cases (oft en with much younger onset than typical sporadic cases) with identical neuopathological features may be a result of FTDP-17 associated with specifi c mutations in the tau gene.
Th e cardinal clinical features of CBS, initially described with this CBD pathology, are no longer felt to be pathognomonic for this disease. CBD is thus a pathological diagnosis with varying clinical presentations .
Epidemiology
CBD is a rare neurodegenerative disease and its exact incidence and prevalence are unknown. In a series of 143 patients with parkinsonism seen at a movement disorders center and proceeding to autopsy, four (2.8%) were diagnosed neuropathologically with CBD. Th ose patients who had neuropathological assessment, however, represented only approximately 8% of patients admitted to the hospital for parkinsonism and less than 5% of patients attending outpatient clinics [ 8 ] . By assuming that CBD accounts for approximately 1% of patients diagnosed clinically with parkinsonism at movement disorders clinics and estimating the number of diagnoses that might be missed, the incidence of CBD has been estimated at 0.62/100 000 to 0.92/100 000 and prevalence in the United States has been estimated at 13 000 to 20 000 [ 9 ] .
Pathology
As discussed in the introduction of this chapter, neuropathological criteria for CBD emphasize the histopathological fi ndings of tau-immunoreactive lesions in addition to ballooned neurons, cortical atrophy, and nigral degeneration ( Table 5 .1 ) [ 7 ] . Th e ballooned achromatic neurons, which were once emphasized as a major component of the histopathology and gave the disorder its original name, are now believed to be non-specifi c, seen in varying numbers in many other neurodegenerative disorders and closely resembling Pick's cells of PiD. Th e Offi ce of Rare Diseases notes that the pathology found in some patients can be mixed, with features of both CBD and other disorders, usually also neurodegenerative in nature. To classify a mixed pathological diagnosis, the autopsy fi ndings must fully meet the criteria for CBD and for the pathological diagnosis that coexists [ 7 ] . Schneider et al . reported that 6 of 11 CBD cases manifested neuropathological overlap; coexistent disorders included AD, PSP, Parkinson's disease (PD), and hippocampal sclerosis [ 10 ] . Other studies have also emphasized overlap with AD, PSP, synucleinopathies, and argyrophilic grain disease [ 11 -13 ] . One study found that only 2 of 8 CBD cases had pure CBD pathology [ 12 ] . In a recent review of neuropathological fi ndings in a series of PSP patients, 32% of the cases reviewed showed coexistent CBD changes [ 14 ] .
Central to the diagnosis of CBD is the presence of abnormal tau aggregations, seen by special staining of pathological specimens. Tau is typically considered a neuronal microtubule-associated protein. However, its presence is also now recognized in astrocytes and oligodendrocytes [ 15 ] . Six tau isoforms are found in human adult brains, resulting from alternative splicing patterns. Th e variations in splicing of exon 10 generate isoforms containing either three (3R-tau) or four (4R-tau) microtubule-binding repeats. Normal adult human brains express approximately equal levels of 3R-tau and 4R-tau, but this ratio is changed in pathological processes, such as when mutations disrupt normal exon 10 splicing [ 16 ] . Most cases of CBD are thought to be associated with up-regulation of 4R-tau containing exon 10 [ 16 ] . In both CBD and PSP, 4R-tau accumulations are prominent in the cerebral cortices while basal ganglia and brainstem accumulations are immunopositive for 4R-tau and occasionally 3R-tau [ 15 ] .
Abnormal tau immunoreactivity is found in both the neurons and the glia. In neurons, tau immunohistochemistry reveals diff use or granular cytoplasmic staining, pretangles, and small neurofi brillary tangles. Th ese probably account for the corticobasal inclusions found in subcortical gray matter regions including the substantia nigra. Tau immunoreactive threads in both neurons and glia are numerous in gray and white matter. CBD pathology includes astrocytic plaques with tau deposition largely in the distal processes of astrocytes. Th ese astrocytic plaques are distinct from tuft ed astrocytes found in PSP, where tau is deposited more proximally to the cell body as well as in distal processes. While CBD and PSP both demonstrate oligodendroglial inclusions, coiled bodies, and threads, the astrocytic changes can distinguish the two diagnoses [ 7 , 15 ] . In addition, while threads are numerous and diffuse in CBD, they are rarely seen in the cerebral cortices in PSP, although they may be dense in other areas [ 17 ] .
A recent neuropathological study has discovered the presence of TAR-DNA-binding protein 43 (TDP-43) in a subset of patients with CBD pathology. TDP-43 is a protein pathologically deposited in the disorder currently termed frontotemporal lobar degeneration with ubiquitin-positive inclusions and TDP-43-immunoreactive inclusions (FTLD-U) as well as in amyotrophic lateral sclerosis (ALS). In 15.4% of CBD cases, TDP-43-positive inclusions were seen in various patterns. TDP-43 pathology was also seen in 25.8% of AD cases, but was not found in PiD or PSP [ 18 ] . Th ere was no clear clinical correlation with the presence of TDP-43 inclusions in CBD. Th e signifi cance of the fi ndings remains unclear other than highlighting the overlap between CBD, CBS, and FTLD-U, discussed further in the following sections .
Genetics
CBD is generally considered a sporadic disorder, although a small number of families with apparent autosomal dominant inheritance have been described. However, it is now recognized that certain inherited mutations in the tau gene can result in pathology identical to that of sporadic CBD; for example, P301L [ 19 ] and N296N [ 20 , 21 ] mutations (with or without the CBS clinical phenotype described later in the chapter). Other tau mutations, to date lacking pathological correlation, can result in a familial CBS; for example, P301S [ 22 ] G289R mutations [ 23 ] . Th ere is no consensus in the literature as to whether these cases should be classifi ed primarily as CBD owing to defi ned mutations or as FTDP-17 with CBDlike pathology. Th e failure to identify a mutation in one family may be related to the use of archival rather than fresh samples [ 24 ] . Another family without a defi ned mutation had one member with CBD pathology and a sibling with PSP pathology, suggesting an underlying tau process distinct from that in sporadic CBD [ 25 ] . Although no tau mutations have been found in sporadic CBD to date, evidence does support involvement of the tau gene. An analysis of tau polymorphisms in CBD has shown that the frequencies of H1 tau haplotypes and H1/H1 genotypes are signifi cantly higher in patients with CBD compared to controls [ 26 ] . All seven CBD cases in a separate report similarly demonstrated the H1 haplotype and H1/H1 genotype [ 12 ] . Th e H1 tau haplotype has also been associated with PSP [ 26 ] , suggesting a common genetic predisposition to these two disorders. In a recent evaluation of patients with clinical pictures suggestive of PSP, CBS, or combined PSP and CBS, the haplotype found was H1 in over 90% of each of the three subgroups [ 27 ] .
In patients with sporadic and familial CBS, the most common genetic causes found are mutations in the gene coding for the protein progranulin ( PRGN ) [ 13 , 28 -32 ] . Neuropathological fi ndings in these patients are more consistent with FTLD-U rather than CBD. In addition to tau and PRGN mutations, other genetic causes of a CBS have included a sporadic spinocerebellar ataxia mutation (SCA-8) [ 33 ] and a hereditary prion protein mutation in a large family where one of the individuals was diagnosed with CBS [ 34 ] . Consistent with the diverse genetic processes underlying CBS as compared to CBD, tau haplotype studies have shown both association of CBS with certain tau haplotypes [ 35 ] and lack of such an association [ 36 ] .
Animal models
No widely studied animal models of CBD currently exist. Various worm, fl y, and mouse models for tauopathies have been used to study this class of diseases in general and are well described in a recent review [ 37 ] . Certain transgenic mouse models are more appropriate for consideration in CBD than others. CBD neuropathology is most notable for the presence of astrocytic plaques and prominent tau-positive neutropil threads. Th us, those models producing similar tau-related pathological changes may be more appropriate for ongoing study in the context of CBD [ 38 -40 ] .
Clinical fi ndings
Initial reports of CBD described hallmark clinical features including asymmetric disease, parkinsonism, tremor, limb dystonia, gait abnormalities, myoclonus, alien limb phenomena, cortical sensory loss, and apraxia [ 1 , 2 , 4 , 5 , 41 ] . Only a small number of patients in each of these series had pathological correlations.
Since the initial descriptions, it has become clear that the clinical syndrome of CBS does not correlate reliably with CBD. While the pathology may reveal CBD, patients meeting clinical criteria for CBS also have a wealth of other neuropathological diagnoses including PD [ 8 ] , PSP [ 42 -46 ] , PiD [ 43 -47 ] , AD [ 6 , 44 , 48 , 49 ] , frontotemporal dementia (FTD) without distinctive histopathology [ 8 ] , FTLD-U [ 13 , 31 , 32 ] including motor neuron disease inclusion dementia (MNDID) [ 50 ] , Creutzfeldt-Jakob disease (CJD) [ 44 , 51 -53 ] , sudanophilic leukodystrophy [ 43 ] , and non-specifi c pathology ( Figure 5.1 ) . Because of the relative rarity of CBD, it is diffi cult to calculate the positive predictive value of a premortem diagnosis of CBS as has been done for other disorders with parkinsonism. Various clinical presentations and diagnoses have been described in patients with CBD pathology ( Figure 5 .1 ), including clinical syndromes mistaken for PSP [ 8 , 13 , 45 , 54 -56 ] , multiple system atrophy (MSA) [ 13 , 56 ] , diff use Lewy body disease (DLBD) [ 56 ] , non-specifi c parkinsonism [ 8 , 56 ] , FTD [ 12 , 13 , 45 , 57 , 58 ] , PiD [ 13 , 56 ] , chorea [ 57 ] , AD and other dementias [ 13 , 56 , 57 , 59 ] , and spastic paresis [ 60 ] . PSP, FTD, and progressive non-fl uent aphasia (PNFA) are the most common non-CBS clinical presentations reported with CBD .
In the next section, fi rst discussed are the clinical features reported in classical CBS (oft en lacking confi rmatory pathology) and then the clinical features reported in patients proven to have CBD at postmortem examination are reviewed.
Corticobasal syndrome
Th e core features of CBS are a progressive asymmetrical akinetic-rigid syndrome and associated higher cortical signs, most prominently apraxia [ 4 , 41 , 61 , 62 ] .
Movement disorders
CBS is an atypical parkinsonism. Symptoms typically start unilaterally, with the arm more commonly aff ected at presentation than the leg [ 41 ] . Common initial complaints include clumsiness, incoordination, stiff ness, or jerking of the aff ected arm [ 41 , 62 ] . On examination, this limb is typically found to be akinetic, rigid, and apraxic, sometimes associated with dystonia [ 41 ] . In a predominantly clinical series, 95% of patients had at least two of the parkinsonian signs of bradykinesia, rigidity, tremor, and gait disorder [ 61 ] . Th e initial involvement of one arm tends to progress over two years, with subsequent involvement of the contralateral arm or the ipsilateral leg and eventually general disability [ 62 ] . Th e parkinsonism of CBS characteristically fails to respond to levodopa and this has been suggested as a possible diagnostic criterion for the disease [ 61 -63 ] .
While tremor can be present and has been reported in 30-55% of patients with CBS [ 61 , 64 ] , the tremor tends to be diff erent from that seen in idiopathic PD [ 61 ] . It may begin as a postural and action tremor and only rarely has a resting element. It is oft en jerky in appearance [ 62 ] . Semi-rhythmic bursts of myoclonus can falsely give the appearance of a tremor at rest. Th e tremor may progress to myoclonus [ 62 ] .
Movement disorders other than the classic asymmetrical akinetic-rigid syndrome are also common in CBS. Dystonia is present in 59-71% of individuals in various series mixing cases of clinical and pathological diagnoses [ 4 , 61 , 64 ] . In a study of 36 patients with CBS, 33% had dystonia at the initial evaluation, but 83% had dystonia at their last follow-up [ 41 ] . Dystonia is present oft en at rest rather than being purely action-induced. Typically, the dystonia aff ects the involved arm and hand at onset [ 41 , 62 , 64 ] , with 92% of CBS patients with dystonia exhibiting upper limb involvement [ 64 ] . When symptoms begin in the leg, dystonic inversion of the foot can be seen [ 62 ] , with 28% of CBS patients with dystonia developing leg involvement [ 64 ] . Th e head, neck, and trunk are less oft en involved. In a series looking specifi cally at dystonia in CBS, 74% of the patients with dystonia developed associated fi xed postures and 42% had accompanying pain, most commonly in a dystonic hand [ 64 ] .
Myoclonus has been reported in 55-93% of patients with CBS [ 4 , 41 , 61 , 64 ] . As mentioned, the myoclonus may evolve from a postural tremor. It tends to be action-and stimulus-induced and involves the distal arm, oft en in association with dystonia. Here the dystonia at rest may result in myoclonus not associated with voluntary activation of the limb. Rarely, a similar presentation can be seen in the leg [ 62 , 65 , 66 ] .
Other movement disorders occurring in association with CBS include athetosis and orolingual dyskinesia [ 4 , 64 ] . Postural instability and falls are more common later in the disease course and are oft en multifactorial, related to parkinsonism, dystonia, and lower limb apraxia. In the rarer cases where leg involvement is prominent at onset, instability may occur earlier [ 62 ] .
Higher cortical dysfunction
In addition to the akinetic-rigid syndrome, higher cortical signs are a classic component of the CBS picture, present in 93% of patients [ 61 ] . Th ese include apraxia, alien limb phenomena, cortical sensory loss, frontal lobe refl exes, dementia, and aphasia [ 4 , 61 ] . Apraxia is the most common higher cortical fi nding in most series, with various categories of apraxia seen ( Table 5. 2 ). Ideomotor apraxia is the most frequently recognized apraxia in CBS, with some patients demonstrating an overlapping ideational apraxia [ 67 ] . Limb-kinetic apraxia has also been reported as the dominant apraxia in CBS [ 68 ] . While it is the initially aff ected limb that typically becomes most profoundly apraxic, the evaluation of this is oft en hampered by the presence of the dystonia and parkinsonism [ 62 ] . To compensate for this, formal evaluation of apraxia has usually been conducted using the limbs least aff ected by the primary motor disorder [ 67 ] . In some patients, symptoms of apraxia can be the presenting complaint, as in the case of a surgeon who fi rst noticed that he had "forgotten" how to glove, tie knots, and use instruments with his left hand [ 4 ] .
Alien limb phenomena (ALP) are variably present in CBS, occurring in 42-67% of patients [ 4 , 41 , 61 , 64 ] . Th e movements are not always described, however, and debate remains about the proper defi nition of alien limb behavior [ 62 , 69 ] . Patients may dissociate themselves from the limb, calling the limb "it" and feeling as though it has a mind of its own [ 62 ] . Various types of ALP are known ( Table 5. 3 ), including intermanual confl ict, mirror movements, enabling synkinesis, grasping, impulsive groping, magnetic apraxia, utilization behavior with compulsive manipulation of tools, and purposeless wandering [ 69 ] . Attempts have been made to divide ALP into frontal, callosal, and more recently, posterior subtypes, but the validity of these groupings remains unclear [ 69 ] .
An early series of CBS patients (some with pathologically proven CBD) described ALP as including uncontrollable wandering, grasping behaviors, and interference with the contralateral limb, either as a foreign presence or simply out of voluntary control [ 41 ] . Involuntary phenomena described in case reports of pathologically-proven CBD include levitation and interference with the other arm's movements [ 1 ] , involuntary head scratching [ 2 ] , arm levitation and tentacle-like movements of the fi ngers [ 5 ] , uncontrollable repetitive tasks including putting on and taking off glasses and moving tissues in and out of a purse [ 4 ] , levitation and touching of the lips [ 4 ] , and elevation, wandering, and spontaneous paddling movements [ 70 ] . Bilateral involuntary movements have been reported in two CBD patients: in an early series, one man had levitation of the left hand with touching of the lips and repetitive involuntary movements of the right arm toward the face [ 4 ] , while a recent report details continuous tactile pursuit with the left hand and a levitating tactile avoidance response with the right hand [ 71 ] .
Given the parietal localization of signs of higher cortical dysfunction in CBS, it is not surprising that many of the descriptions of ALP in CBS are consistent with the proposed posterior subtype of ALP, where the alien movements tend to appear purposeless and wandering rather than the more purposeful movements described in frontal and callosal ALP. Simple levitation, however, can be seen in parietal lesions without ALP, which is why one set of proposed research criteria for CBS specifi cally excluded actions that appear to be simple levitation [ 63 ] . Simple levitation is a common source of misdiagnosis in CBS. Personal experience with CBS suggests that compulsive groping and grasping (magnetic apraxia) is a particularly common form of ALP in CBD . Cortical sensory loss was present in 14 of the 16 patients in an early series and was the sole initial symptom in three of these patients [ 4 ] . It was present in 33-59% of patients in other clinical series [ 41 , 61 , 64 ] . Aff ected patients oft en complain of numbness and ting ling and some have been treated with inappropriate -and unsuccessful -carpal tunnel release [ 62 ] . Examination may reveal normal primary sensory modalities with impaired joint position sense and twopoint discrimination. Agraphesthesia and astereognosis may also be present [ 62 ] .
Th e prominent presence of cognitive dysfunction in CBD has become increasingly evident; this is discussed further in the following sections. While dementia was initially considered an exclusion criterion for CBS [ 63 ] , it is now clear that cognitive impairment frequently accompanies CBS. Neuropsychological testing performed in patients with CBS shows global deterioration, executive dysfunction, and impairments in language and visuospatial functioning [ 72 , 73 ] . Oft en calculation is also impaired [ 74 ] . In general, semantic memory appears to be minimally aff ected, at least early in the disease course [ 62 , 72 , 73 ] . Language dysfunction is part of the cortical dysfunction seen in CBS. It has been noted with increased frequency in recent studies, possibly because initially it was overshadowed by prominent motor features [ 75 ] . In early reports of CBS, aphasia was reported in 10-21% of cases [ 4 , 61 ] . A review of cognitive processes in CBS subsequently has found aphasia reported in 31% of clinically diagnosed cases [ 73 ] . Half of CBS patients studied showed evidence of aphasia syndromes on Western Aphasia Battery testing [ 75 ] . In a separate assessment of 10 patients with CBS, only two had clinically apparent aphasia, but the majority showed some degree of language impairment, particularly on phonologic and spelling tests [ 76 ] . When present, the aphasia typically is non-fl uent or anomic [ 73 , 75 ] .
Other clinical manifestations of corticobasal syndrome
In addition to the classic features of a movement disorder with higher cortical dysfunction, patients with CBS are described as having pyramidal fi ndings, impaired ocular motion, impaired eyelid motion, dysarthria, and dysphagia [ 4 , 61 , 64 ] . Of these, pyramidal signs such as hyperrefl exia (oft en asymmetrical) and extensor plantar responses are the most commonly reported [ 4 , 61 , 62 ] .
Oculomotor abnormalities have been reported in 66.7% of CBS patients [ 64 ] , requiring diff erentiation from the closely related PSP. Studies of patients with CBS and clinically diagnosed PSP suggest that CBS patients have equally aff ected horizontal and vertical eye movements and demonstrate slowed initiation of saccades with markedly increased saccadic latencies. Th is is in contrast to PSP, where vertical saccades tend to be more aff ected than horizontal and where the prominent impairment is decreased saccadic velocity rather than abnormal latency [ 77 ] . In a recent study examining various clinically diagnosed neurodegenerative diseases, vertical oculomotor abnormalities were universally more prominent than those in the horizontal direction. PSP was the only condition that exhibited abnormal saccadic velocity. While PSP showed increased latency only with vertical saccades, CBS and AD showed increased latency with both vertical and horizontal saccades. Saccadic gain was most impaired in the PSP group but was also seen in CBS and AD patients. FTLD subsets showed variable but less prominent oculomotor fi ndings [ 78 ] . Case reports describe Balint's syndrome [ 79 ] , visuomotor ataxia [ 80 ] , and visual hallucinations [ 81 ] occurring within the context of the clinical syndrome of CBS. Impaired smell has been reported recently in a CBS cohort [ 82 ] . Depression, and to a lesser extent, apathy, irritability, and agitation, are neuropsychiatric symptoms observed in CBS patients [ 83 ] . A combination of spastic dysarthria and pathological laughter and crying was reported as a presenting feature in two women who developed typical features of CBS several years later [ 84 ] .
The Pick complex
Because of the overlap of the motor symptoms of CBS with cognitive and language dysfunction, and because of the potential for several diff erent pathological disorders to cause CBS, it has been suggested that CBS and CBD be categorized under the broad heading of the Pick complex [ 45 , 85 -88 ] . Th is umbrella term has been proposed to include a number of diagnoses [ 45 , 86 ] , most prominently PiD, FTD, primary progressive aphasia (PPA), PNFA, semantic dementia, PSP, and CBS/CBD [ 45 , 86 , 87 ] . In a series of 60 patients with these clinical diagnoses and subsequent autopsy, 45 had pathology compatible with FTD/ Pick complex. Ten of the remaining 15 patients had AD on autopsy and the other fi ve had heterogeneous fi ndings. Of the 45 patients with FTD/Pick complex pathology, 24 had tau-negative pathology and 21 had tau-positive pathology. Th e most common histological fi ndings were (tau negative) motor neuron disease-type inclusions (40%). CBD was the second most common pathological diagnosis (27%) [ 87 ] . Similar fi ndings were reported by a second group, where of 61 patients with clinical variants of FTD, 31 had tau-positive inclusions and 30 had tau-negative neuropathology. Nine patients (15%) were diagnosed with CBD [ 89 ] .
Within the context of the Pick complex, a concept has been proposed describing the evolution of clinical syndromes over time. Syndromes can be labeled fi rst, second, and third based on the clinical diagnoses for which criteria are met sequentially over time. Th is concept has been studied in several series from the same group [ 85 , 87 , 88 ] . Th e most recent series of 55 patients with CBS showed that of the 19 patients with a motor presentation of CBS, 18 progressed to a second syndrome of either FTD or progressive aphasia (PA). Seven patients then progressed to a third syndrome of either FTD or PA. Of the 36 patients with cognitive onset of CBS, all 15 patients starting with clinical features of FTD progressed to show evidence of both CBS and PA as second and third syndromes in varying orders. Twenty-one patients initially had symptoms of PPA, 12 of whom had both secondary and tertiary syndromes of CBS and FTD and nine of whom only had a secondary syndrome of CBS with no further evolution to a third syndrome at the time of the report. Autopsy fi ndings were available for 19 of these patients, with evidence of CBD, PSP, CBD/PSP mixed pathology, prion disease, PiD, AD, and FTD with motor neuron disease-type inclusions. All patients with CBD demonstrated CBS at some time during the course of their illness, but sometimes not until the later stages [ 88 ] . 
Clinical features of corticobasal degeneration
Th ree series of patients with pathologically proven CBD describe clinical features of 42 patients [ 56 , 59 , 90 ] . In the earliest of these series, the presentation was consistent with classic descriptions of CBS. Asymmetric limb clumsiness with or without rigidity (50%) and tremor (21%) were the most common early symptoms. Findings most commonly seen at the initial neurological consultation -an average of three years aft er symptoms started -were unilateral limb rigidity (79%), bradykinesia (71%), ideomotor apraxia (64%), postural imbalance (45%), unilateral limb dystonia (43%), and cortical dementia (36%) [ 56 ] .
In the subsequent series, involving 28 patients, early and prominent cognitive dysfunction was more common than the classic motor presentation of CBS. In the series reported by Grimes et al ., only 4 of the 13 patients had CBS. Nine patients had early cognitive impairment, six of whom were given the clinical diagnosis of AD. All but 1 of the 13 patients in this series had cognitive dysfunction before death. Five of these patients also had early language dysfunction [ 59 ] . In the most recent series, 53.3% of patients with CBD presented solely with a cognitive complaint, 20% presented solely with a motor complaint, and 26.7% presented with mixed complaints. Cognitive complaints involved memory, language, and other cognitive skills. Only six of these patients received a correct diagnosis of CBD before their deaths, fi ve of whom had motor signs on initial testing [ 90 ] . In all three series, almost all patients developed at least one extrapyramidal motor sign prior to death [ 56 , 59 , 90 ] .
Neuropsychological testing of CBD patients demonstrates diffi culties with learning tasks, word fl uency, verbal comprehension, perceptual organization, and cognitive fl exibility [ 57 ] . Aphasia has been reported in 44% of pathologically diagnosed cases [ 73 ] , with early language dysfunction present in 29%, 38.5%, and 46.7% of CBD patients in the above series [ 56 , 59 , 90 ] . Th e frequency of language dysfunction increases over the course of the disease, with 50-71.4% of patients demonstrating language dysfunction prior to death [ 56 , 90 ] . In one CBD series, language dysfunction -including eff ortful speech, word-fi nding diffi culties, and/or handwriting diffi culty -was the most commonly reported early complaint [ 90 ] . Apraxia of speech (AOS) has also been reported both as the sole presenting feature of CBD and in combination with aphasia [ 70 , 91 ] , with a recent review emphasizing that a subset of both CBD and PSP patients may have only AOS or PNFA at disease onset without associated parkinsonism [ 92 ] . Preliminarily, prominent AOS may be more PSP-related and prominent language dysfunction may be more likely CBD-related, but this association needs further confi rmation [ 92 ] .
CBD patients lacking asymmetrical parkinsonism at onset of disease, especially those presenting with cognitive disturbances, are the most likely to be misdiagnosed. An absence of ideomotor apraxia and the alien limb sign also contribute to misdiagnosis [ 59 , 90 , 93 ] .
Th e previously discussed concept of fi rst, second, and third syndromes in patients with CBS is obviously relevant to cases where the pathology is proven to be that of CBD. In the series reporting symptom and syndrome progression over time, the ten patients with a pathological diagnosis of pure CBD refl ected various orders of syndrome evolution. All ten eventually developed features of CBS. However, only two started with a motor syndrome, both later displaying FTD and PA syndromes. Th e other eight CBD patients had cognitive presentations. Four began with FTD and four with PA symptoms. All but one patient demonstrated all three syndromes of CBS, FTD, and PA, emphasizing the clinical heterogeneity of the disorder. Half of the ten exhibited CBS as the third syndrome, underscoring that [ 88 ] . Clinical features of CBD are summarized in Table 5 .4 .
Other clinical manifestations
In addition to classic CBS features and prominent cognitive impairment, patients with CBD demonstrate varying degrees of pyramidal fi ndings, visual and oculomotor complaints and fi ndings, and depression. Pyramidal fi ndings include hyperrefl exia and extensor plantar responses [ 56 , 59 , 94 ] and may be a source of misdiagnosis [ 93 ] . One unusual patient with CBD demonstrated a progressive spastic paraparesis for fi ve years before extrapyramidal signs became evident [ 60 ] . Visuospatial complaints have been presenting concerns for patients in multiple CBD series and reports [ 56 , 90 , 94 ] . Presentation of CBD as a posterior cortical atrophy syndrome results in clinical fi ndings such as homonymous hemianopia, visual neglect, optic ataxia, visual agnosia, and simultagnosia [ 56 , 59 , 90 , 94 ] . Apraxia of eyelid opening and abnormalities of oculomotor movements including apraxia of gaze, gaze impersistence, impaired saccades, and supranuclear gaze palsies are also described in CBD [ 1 , 4 , 5 , 56 , 59 ] . Some kind of visuospatial or ocular abnormality is seen in 50-62% of CBD patients prior to death [ 56 , 90 ] . No studies have examined diff erences in eye movement abnormalities in cases of pathologically proven CBD compared to PSP.
While the presence of neuropsychiatric features has not been assessed formally in CBD, behavior changes are common, as refl ected in the overlap with FTD. Depression has been reported in approximately 30% of patients at symptom onset and approximately 40% prior to death [ 56 , 90 ] . 
Natural history
CBD symptom onset is typically in the sixth and seventh decades of life [ 4 , 5 , 45 , 56 ] . Mean ages at onset reported are 60.9, 63, and 63.9 years, with a range of 45-75 years [ 45 , 56 , 90 ] . CBS has been reported in patients as young as 27 and 28 years old, one case of which was associated with a tau mutation and a positive family history. Neither case had associated neuropathology [ 22 , 95 ] . Presentation at a young age should prompt investigation for tau or PRGN mutations or some other symptomatic cause (e.g. prion disease) rather than assuming a diagnosis of sporadic CBD. Men and women are equally aff ected by CBD [ 45 , 56 , 59 , 90 ] . Th e onset of CBD is insidious and it is relentlessly progressive [ 4 , 41 , 56 , 62 ] . Mean disease duration was 7.9 years and 5.4 years in two pathology series, with ranges of 2.5-12.5 years and 2.0-7.5 years, respectively [ 56 , 90 ] . In a study of the natural history of CBD, statistically signifi cant predictors of shorter survival included fi rst visit fi ndings of bilateral bradykinesia, a frontal syndrome, or the presence of at least two of three extrapyramidal features (tremor, rigidity, or bradykinesia). All patients with available postmortem cause-of-death information died of bronchopneumonia [ 56 ] .
Investigations
Discussion of investigations for CBD is complicated by the fact that most reports involve primarily patients with CBS without pathological confi rmation. Th is will be re-emphasized throughout the following section. Typically, routine blood, urine, and cerebrospinal fl uid (CSF) analyses are normal in CBD. Multiple studies have investigated possible CSF biomarkers in CBS compared to controls and other disorders with parkinsonism, particularly PSP. Researchers have measured CSF tau [ 96 -100 ] , orexin [ 101 ] , β-amyloid [ 102 ] , neurofi lament heavy chain component [ 103 ] , and homovanillic acid levels [ 104 ] . Levels of CSF tau compared to controls and compared to PSP and other neurodegenerative conditions have been variable and all of these studies are limited by the lack of pathological confi rmation, thus allowing for overlap between studied groups. Further studies are needed to determine whether any of these possibilities will be a reliable biomarker for these conditions that require pathological confi rmation.
Neuropsychological testing
As discussed in the previous sections, cognitive dysfunction, including aphasia, is common in CBD. Tasks of learning and word fl uency were impaired in patients with autopsy diagnoses of CBD and PSP in a recent study; subjects with CBD performed worse on tests of verbal comprehension, perceptual organization, and cognitive fl exibility compared to controls [ 57 ] . Longitudinal neuropsychological assessments in CBD patients show impaired executive, language, and visuospatial processes with relatively preserved episodic memory. Th e Mini-Mental State Examination was not sensitive for the defi cits found on neuropsychological testing [ 90 ] .
Patients with CBS have depression (73%), apathy (40%), irritability (20%) and agitation (20%) on the Neuropsychiatric Inventory. General neuropsychological testing has shown the classic asymmetrical apraxias (not surprising, given criteria used for diagnosis) with a dysexecutive syndrome. Th e cognitive profi le of patients with CBS includes a moderate dementia with impaired attention and concentration, verbal fl uency, language, and visuospatial tasks but intact semantic memory [ 72 , 105 ] . 
Neuroimaging
Th e exact role of neuroimaging in diagnosing CBD is still evolving, but it is useful in ruling out contributory focal lesions, at least. For example, anatomical imaging in patients with clinical pictures overlapping with CBS have occasionally shown focal abnormalities suggestive of ischemic lesions [ 43 ] , Fahr's disease [ 106 ] , CJD [ 52 ] , and a thalamic tuberculoma with associated focal cortical atrophy [ 107 ] . Various imaging modalities have been studied in patients with CBS but no pathological confi rmation. Th e most common MRI feature reported in CBS is asymmetrical cortical and cerebral peduncle atrophy, usually contralateral to the clinically more profoundly aff ected side [ 108 -110 ] . Posterior frontal and parietal lobes are usually more severely atrophied. Fluid-attenuated inversion recovery (FLAIR) imaging commonly reveals frontal and/or parietal subcortical white matter changes [ 108 ] , oft en with subtle peri-rolandic hyperintensities that can be bilateral [ 108 , 109 ] . Mild to moderately severe white matter changes have been described in 40-48% of CBS patients [ 64 ] . Basal ganglia changes reported to date have been variable [ 108 , 109 ] .
In pathologically proven CBD, MRI scans have shown cortical atrophy, particularly frontal and parietal, and atrophy of the corpus callosum [ 111 , 112 ] . Unlike imaging studies reported in patients with CBS, MRIs in CBD have usually shown relatively symmetrical cortical atrophy [ 112 , 113 ] . Basal ganglia atrophy has also been reported [ 112 ] . When CBS patients with CBD pathology were compared to CBS patients with other neurodegenerative pathologies, no features were found to be specifi c for CBD [ 111 ] .
Specialized MR techniques such as MRI-based volumetery [ 113 ] , voxel-based morphometry [ 110 ] , MR spectroscopy (MRS) [ 114 ] , and functional MRI [ 109 ] have been investigated preliminarily in CBS, but their utility remains unclear.
Two studies have assessed volumetric MRI in CBD. One found that a model combining the midbrain, pons, parietal white matter, temporal gray matter, brainstem, and frontal white matter volumes could diff erentiate CBD patients from pathologically proven PSP patients and controls, whereas analysis of any one area could not [ 113 ] . Voxel-based morphometry also showed diff erences between CBD and pathologically proven PSP. Semiquantitative analysis in patients with primary extrapyramidal presentations showed that the CBD subgroup had moderate cortical gray matter atrophy and subcortical white matter atrophy while the PSP subgroup had moderate brainstem atrophy. In contrast, CBD patients presenting with prominent cognitive disturbance had severe cortical and moderate subcortical gray matter atrophy with minimal white matter changes, while the PSP patients presenting in this fashion showed moderate cortical gray and subcortical white matter atrophy and mild brainstem and subcortical gray matter atrophy [ 112 ] .
Positron emission tomography (PET) imaging with [ 18 F]-fl uorodeoxyglucose (FDG) in CBS patients shows asymmetrical patterns of glucose metabolism [ 115 -119 ] . Th ese fi ndings, however, simply corroborate the distribution of the underlying process and provide no insight into the nature of the pathology. PET imaging with
, a marker of peripheral benzodiazepine-binding sites expressed by activated microglia, showed that four CBS patients had increased microglial activation in the basal ganglia and cortical regions corres ponding to the locations of abnormalities found on typical CBD neuropathological examination [ 120 ] . Clinical applications of this fi nding need to be further elucidated. CBS SPECT studies show asymmetrical frontoparietal hypoperfusion [ 108 , 109 ] consistent with known localization of clinical fi ndings but without insight into the underlying pathological processes. Striatal fl uorodopa uptake studies have shown variable degrees of asymmetry and extent of caudate and putaminal uptake, with reports of both signifi cant and insignifi cant diff erences compared to typical PD [ 116 , 119 , 121 ] .
One study of transcranial sonography reported that patients with CBS had marked substantia nigra hyperechogenicity compared to clinically diagnosed PSP patients, but pathological confi rmation was lacking for both groups [ 122 ] .
Electrophysiology
In case reports of CBD where it is mentioned, electroencephalography (EEG) has been normal or has shown slow-and sharp wave activity, particularly over the more aff ected hemisphere, and/or diff use bilateral slowing [ 1 , 4 ] . Studies of patients with CBS without pathological confi rmation have demonstrated asymmetrical slowing including focal intermittent slow waves (typically contralateral to the dominantly aff ected limb), intermittent sharp waves, and less commonly, frontal intermittent rhythmic delta activity and slowing of background activity [ 114 , 123 ] .
Electrophysiological studies have been used to assess myoclonus in CBS. No electrophysiological studies have been reported of patients with pathologically proven CBD. Electrophysiological testing of the myoclonus in CBS has found a pattern diff erent from other syndromes with parkinsonism and suggestive of a cortical process, although distinct from classic cortical refl ex myoclonus [ 65 , 124 -126 ] . While most studies suspect a cortical source of the myoclonus, a subcortical origin has also been proposed [ 127 ] . Typically, the electromyography (EMG) pattern shows synchronous short duration bursts (20-50 ms) of upper limb muscle discharges (agonist and antagonist muscles) and a lack of associated large EEG potentials or giant somatosensory evoked potentials (SEPs) [ 65 , 124 -126 ] . Short latencies (approximately 40 ms) are typically reported between stimulus and elicited jerk [ 65 , 124 , 125 ] . In addition, the long-latency responses (LLRs) are reported to be enhanced at rest in CBS patients and to have an abnormally increased amplitude during motor activation [ 125 ] .
Somatosensory evoked potentials are typically but variably abnormal in CBS. Abnormal morphology of the parietal P25-N33 component [ 65 ] , abnormal morphology of the parietal N20-P25 complex [ 126 ] , and minimal abnormalities in parietal SEP responses but absent frontal SEP responses [ 125 ] have all been reported .
Transcranial magnetic stimulation (TMS) in CBS patients shows variable disruption of the ipsilateral silent period indicating callosal pathology [ 128 ] . A study of TMS in various syndromes with parkinsonism showed persistent callosal impairment in both CBS and PSP groups with intact ipsilateral silent periods in MSA and ideopathic PD patients [ 129 ] . Recently, normal TMS fi ndings in a patient with CBS supported consideration of an alternate diagnosis, ultimately shown pathologically to be CJD [ 51 ] .
Management
At present, the etiology and pathogenesis of CBD are unknown. In the future, treatments designed to interfere with the various processes underlying the pathological aggregation of phosphorylated 4R-tau may eff ectively slow the inexorable progression of the disease. It is likely that breakthroughs in the basic treatment of any of the related tauopathies (e.g. PSP 
Pharmacological therapies
All treatments suggested to provide some benefi t in CBS and CBD are based on open-label anecdotal reports, usually involving small numbers of clinically diagnosed patients and relying exclusively on subjective reports of response.
Parkinsonism
Th e parkinsonism in CBS is typically unresponsive to levodopa therapy, although transient mild to modest improvements have been reported [ 4 , 61 , 64 ] , including in one of four pathologically confi rmed patients [ 56 ] . No reported patients with CBS have had a sustained response to levodopa or other dopaminergic therapies [ 130 ] . A single report describes levo dopa-induced dyskinesia aft er 18 months of levodopa therapy (800 mg/day) in a patient with confi rmed CBD, with decreased dyskinesia but worsening parkinsonism following dose reduction [ 131 ] . A small percentage of patients with CBS have reported worsening of motor symptoms with levodopa [ 61 ] . While levodopa is the most common anti-parkinsonism medication used, dopamine agonists, selegiline and amantadine, have also been tried, typically with minimal benefi t [ 61 , 64 ] . Th ere are limited reports of improvement in parkinsonism with benzodiazepines, anticholinergic medications, baclofen, anticonvulsants, and propranolol [ 61 ] .
Dystonia
Occasional improvements in dystonia with levodopa, benzodiazepines, anticholinergic drugs, and baclofen have been reported in CBS [ 61 ] . Individuals treated with baclofen, dantrolene, and diazepam in a separate series showed no benefi t [ 4 ] . Targeted botulinum toxin injections may be the most useful intervention, with the majority of patients receiving it describing some improvement [ 61 , 64 , 132 ] . Th ree patients with a clenched fi st owing to CBS experienced signifi cant improvement in pain and muscle relaxation aft er botulinum toxin injections targeting the lumbrical and fi nger fl exor muscles, although function remained unchanged [ 132 ] .
Myoclonus
Benzodiazepines, particularly clonazepam, have been used in patients with myoclonus in CBS to some eff ect [ 4 , 61 , 64 ] . Although no improvements with valproic acid, piracetam, or diazepam were obtained in one series [ 4 ] , trials of valproic acid, gabapentin, levetiracetam, piracetam, and felbamate have been recommended [ 133 ] . Levetiracetam 1000 mg/day partially decreased myoclonic and involuntary movements in one recent case report [ 23 ] .
Tremor
Anticonvulsant medication and propranolol targeting tremor are benefi cial only occasionally [ 61 ] . Other considerations include benzodiazepines, anticholinergic drugs, levodopa, primidone, and nadolol [ 133 ] . [ 133 ] . Abulia may respond to AChEI, psychostimulants, and activating antidepressants [ 133 ] and neuroleptics may be useful in patients with dyscontrol [ 61 , 133 ] .
Neuropsychiatric and cognitive features

Physical therapy and speech therapy
Physical and ancillary therapies in patients with CBS are rarely reported. Th e profound apraxia in CBS may reduce responses to physical therapy known to help other disorders with parkinsonism. Oft en it greatly limits the patient's ability to learn new strategies when attempting to improve physical disabilities. Constraint-induced movement therapy, now used with increasing frequency in stroke patients, was reported to provide benefi t for over two years in one CBS patient, with variable results in others [ 133 ] . Long-term locomotor training has also been reported to benefi t a patient with mixed CBS and PSP features [ 134 ] . Th e potential benefi ts of speech therapy for CBD-related aphasia and speech apraxia are unknown.
Surgery
While formal studies are lacking, surgery is unlikely to help patients with CBD, as with most other atypical parkinsonism syndromes. One patient with severe myoclonus and painful dystonia showed no improvement with stereotactic thalamotomy and right dorsal rhizotomy of the fi ft h cervical to fi rst thoracic spinal nerves [ 4 ] . In a series of referrals for failure of deep brain stimulation (DBS), fi ve were related to misdiagnosis, including one patient with CBS mistaken for essential tremor [ 135 ] . Th ere are a number of patients who have received DBS of the subthalamic nucleus or globus pallidus internus without benefi t (unpublished data).
Palliative therapy
Given the relentless progression of CBS, palliative interventions are an important aspect of continuing care. Physical supports such as wheelchairs are oft en required, particularly when postural instability is prominent. When dysphagia is present, percutaneous endoscopic gastrostomy tube placement must be discussed, although this cannot fully alleviate the risk of aspiration. Family and caregiver support is critical [ 130 ] . In the late stages, palliative and hospice programs may be appropriate where available.
Conclusion and future directions
Given the broadly based multisystem nature of CBD, it is unlikely that highly eff ective symptomatic treatments will be developed. Given this and the relentless progression of the disease, the research emphasis needs to focus on understanding the pathogenesis of CBD and developing neuroprotective or disease-modifying strategies. Understanding the pathologic al causes of CBS and CBD and developing potential treatments are closely linked. Better methods of distinguishing the various pathological causes of CBS are clearly needed. Such eff orts are academic, however, unless eff ective disease-modifying therapies are found. Th e two most common general categories of neurodegenerative disease associated with the CBS phenotype are tauopathies and TDP-43 proteinopathies. Treatments directed at altering the pathogenesis of disease will likely diff er between these two groups, although treatments may be eff ective for several diff erent disorders with each sub-category (e.g. CBD, PSP, FTDP-17 owing to tau mutation).
As for all neurodegenerative diseases, multiple pathogenic mechanisms have been proposed in the tauopathies, including mitochondrial dysfunction, oxidative stress, abnormal axonal transport, infl ammation, and particularly disturbances in tau metabolism. Putative disease-modifying therapies could be proposed in all of these categories. With respect to tau metabolism, it is known that hyperphosphorylation of tau is a characteristic feature of the tauopathies. Proposed therapeutic targets include decreasing kinase activity or increasing phosphatase activity. Th e former approach is probably more within the realm of possibility, with two glycogen synthase kinase 3-β (GSK-3β) inhibitors available for clinical use: lithium and valproic acid. Indeed, lithium has been demonstrated to ameliorate disease progression in transgenic mouse models of tauopathy [ 136 ] and currently there is a Phase II study of the safety and tolerability of lithium combining patients with CBS and PSP. Alternatively, CBS could be combined with FTD presenting with PNFA (more predictive of underlying CBD pathology). Th is approach is being used to study the eff ects of NAPVSIPQ [ 137 ] , a neuroprotective peptide that stimulates microtubule assembly and reduces tau phosphorylation (A. Boxer, personal communication). Th e lumping approach recognizes that, although CBS may be a result of a variety of pathologies, the majority of such patients have an underlying tauopathy (particularly if patients with a familial disorder are excluded, removing patients with PGRN mutations). Until more eff ective biomarkers are available, such lumping together of conditions can be justifi ed in order to encourage advances in the treatment of this otherwise untreatable disorder .
